Drug Profile
MK 3207
Alternative Names: MK3207Latest Information Update: 14 Sep 2009
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antimigraines
- Mechanism of Action Calcitonin gene-related peptide antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 11 Sep 2009 Discontinued - Phase-II for Migraine in USA (PO)